Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Growth to be Benefited by Technological Advancements

Increased Prevalence of the Infection Drives
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market

The global pipeline analysis of hospital acquired pneumonia drugs market is driven by the rising incidences of nosocomial pneumonia or Hospital-acquired pneumonia.

Hospital-acquired pneumonia (HAP) or nosocomial pneumonia is one of the leading reasons for mortality and morbidity despite the existence of improved supportive care, antimicrobial, and prevention therapy.

Hospital-acquired pneumonia or nosocomial pneumonia is any pneumonia that is acquired by a patient in the settings of a hospital at least after 48 to 72 hours of being admitted. It is, as such, is much different from community-acquired pneumonia. Generally, bacterial infection rather than a viral one causes hospital-acquired pneumonia. A patient suffering from hospital-acquired pneumonia usually exhibits a combination of leukocytosis or leucopenia, poor oxygenation, hypothermia or fever, and augmented tracheal secretions.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1881

Multidrug Resistance of Hospital-acquired Pneumonia Causing Bacteria Fuels Growth
Nosocomial or hospital acquired pneumonia gives rise to several complications and create complicate the medical condition for patients admitted in hospitals across the globe. Multidrug resistant microorganisms are responsible for the occurrence of these infections. These infections considerably diminish the patient's ability to recuperate and numerous comorbidities also follow, which is likely to support growth of the global pipeline analysis of hospital acquired pneumonia drugs market in the years to come.

These organisms, being multidrug resistant, are immune to the usual antibiotics. Multidrug resistance makes it difficult for the conventional antibiotics to treat the infection acquired in the hospital, which is expected to boost the global pipeline analysis of hospital acquired pneumonia drugs market. Pneumonia is considered one of the most prominent infections caused in the premises of a hospital. Incidences of hospital-acquired pneumonia are quite high in the elderly and infant patients, immunocompromised patients. It also attacks patients going through enteral feeding and in post surgical infections.

Request for Analysis of COVID19 Impact on Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1881

Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne.
Currently there are four drugs authorized for treatment of hospital acquired pneumonia; these include Zosyn (piperacillin/tazobactam), Zyvox (linezolid), Tygacil (tigecycline), and Vibativ (telavancin). Consistent research and development is being conducted in view of introducing more effective treatment options. There are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage, which mainly include biological drugs.

Request a Sample of Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881

Tedizolid phosphate and ceftolozane/tazobactam by Cubist Pharmaceutical, ceftazidime/avibactam by AstraZeneca PLC, amikacin inhale by Bayer Healthcare, plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline are the phase III candidates. Considering the antibacterial efficiency, and current market competition, tedizolid phosphate is expected to be the most preferred drug for treatment of nosocomial pneumonia. Amikacin inhale, an aerosolized drug is intended for sale as a drug device combination. Majority of the drugs in the late stages are biological drugs. Aridis Pharmaceutical holds four investigational drugs against various causative agents of hospital acquired pneumonia, each being monoclonal antibody therapy.

Enquiry before Buying Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1881

Key companies in the market include Achaogen, Inc., Aridis Pharmaceutical, AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer Healthcare, Cubist Pharmaceutical, GlaxoSmithKline, Meiji Seika Pharma Co., Ltd., Merck & Co., and Valneva SE.

More Trending Reports by Transparency Market Research:

https://www.transparencymarketresearch.com/osteoporosis-drug-market.html

https://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html

Contact Us

Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.